ABSTRACT Aim: High-flow nasal cannula (HFNC) therapy provides noninvasive respiratory support for infant bronchiolitis and its use has increased following good clinical experiences. This national study describes HFNC use in Finland during a severe respiratory syncytial virus (RSV) epidemic.
INTRODUCTION
Bronchiolitis is the leading infectious cause of hospitalisation in infancy (1) . In European countries, it is usually defined as an acute respiratory infection with breathing difficulties in infants under 12 months of age (2) and the diagnosis is clinical, based on typical signs and symptoms (3) . As there is no widely accepted consensus on the treatment of infants with bronchiolitis, the therapy tends to focus on maintaining oxygenation and hydration (4) .
High-flow nasal cannula (HFNC) therapy is a relatively new approach to treating, and even preventing, hypoxia in respiratory diseases (5) . It involves administering a heated and humidified mixture of oxygen and air via a nasal cannula at a flow rate of more than 3 L/min, which reduces the dead space and causes continuous distending pressure in the airways (5, 6) .
Physiological studies have shown that when bronchiolitis patients were treated with HFNC, oxygen saturation (SpO 2 ) improved and the work of breathing, respiratory rate and heart rate decreased (6, 7) . HFNC seems to be well tolerated in infants with bronchiolitis (8) , but the research-based clinical evidence on its effectiveness has been insufficient (5, 8) . Some studies have compared infants with bronchiolitis who were treated with HFNC to historical controls who were treated in the same hospital with standard lowflow oxygen administration. The results of these studies were positive, in line with subjective clinical experience (9, 10) . 
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Key notes
This questionnaire-based study evaluated high-flow nasal cannula treatment for infant bronchiolitis in Finland during the 2015-2016 respiratory syncytial virus epidemic. Responses were received from 17 children's hospitals and the mean incidence of HFNC treatments was 3.8 per 1000 per year. Instructions on how to start HFNC were provided more often (71%) than how to wean (61%) and providing weaning advice was associated with shorter weaning times.
In an Italian semi-randomised pilot study, infants hospitalised for bronchiolitis at <12 months of age, and treated with HFNC, presented with lower clinical severity scores, shorter oxygen administration times and shorter hospitalisation stays than controls treated with standard low-flow oxygen (11) . An Australian randomised controlled trial (RCT) published in 2017 comprised 202 infants with moderate bronchiolitis who were <24 months of age and had SpO 2 levels of 90%-94%. Half were randomised to HFNC and the other half to standard low-flow therapy. The groups did not differ in terms of weaning time or the need for intensive care, but treatment failures were less common in the HFNC group (14%) than in the controls (33%) and 60% of the controls that failed to respond were successfully treated with HFNC (12) . Thus, HFNC therapy may have a role to play as rescue therapy for infant bronchiolitis in order to avoid high-cost intensive care.
Five RCT studies are currently being carried out on HFNC therapy in bronchiolitis to our knowledge: one large study in Australia and New Zealand (13) and four other studies that have recorded their protocols in the Clinical Trials Register.
Until now, no evidence-based guidelines have been constructed for HFNC in infant bronchiolitis, simply due to the lack of such evidence. There is a risk that the noncontrolled use of HFNC will expand, with varying indications and protocols that are only based on the experiences of single teams or even single doctors. The aim of this national questionnaire study was to evaluate the use of HFNC for infant bronchiolitis in children's hospitals in Finland and the period we chose was during the 2015-2016 respiratory syncytial virus (RSV) epidemic.
MATERIALS AND METHODS
In this descriptive study, the data were collected by a questionnaire that was specially written for this study and included both quantitative and open qualitative questions. The questionnaire, which covered the indications and practices of HFNC treatment in infants with bronchiolitis, was sent to the head physicians of the paediatric departments of 18 Finnish hospitals that provided inpatient care for young children. Of those, three were university hospitals, 13 were central hospitals and two were large regional hospitals working in close connection with a tertiary university hospital. We received completed questionnaires from 17 hospitals that were primarily responsible for 43 202 (77.5%) of the 55 759 infants born in Finland in 2015, according to official government statistics. The hospital that did not respond was one of the 13 central hospitals.
The questionnaire consisted of questions on the HFNC treatment provided for infants hopitalised for bronchiolitis below the age of 12 months between November 1, 2015 and May 31, 2016, when there was a severe nationwide RSV epidemic. The collected data included the numbers of bronchiolitis patients treated with HFNC and whether the hospital provided its staff with instructions on how to initiate, wean and to cease HFNC therapy. We also asked respondents about the indications for HFNC treatment, including the SpO 2 threshold, the starting, maximum and end settings for gas flows and the SpO 2 oxygen saturations during HFNC. There were also questions about whether nasogastric tubes were routinely used and about the indications and practices for fluid therapy. The questionnaire also requested details on how many HFNC treatments were carried out in the paediatric intensive care unit (PICU) or other intensive care units and how many were carried out on the paediatric ward. The attending doctors were asked to describe, in their own words, what indications they used to start, wean and cease HFNC treatment, including the gas flows they used, the fractions of inspired oxygen (FiO 2 ) and the starting and target SpO 2 levels of the patients. Answers to the open qualitative questions were categorised by the authors as quantitative variables in the analyses.
We did not send the questionnaires to two university hospitals, Tampere University Hospital and Oulu University Hospital, because both these hospitals were involved in an ongoing RCT on the HFNC treatment of infants with bronchiolitis, which started in 2016 during the RSV epidemic (Clinical Trials Register, No. NCT02737280). These two hospitals treated bronchiolitis patients according to the RCT study protocol. In short, infants who were less than six months old and had been hospitalised for bronchiolitis were eligible to be included in the study and the indication for enrolment was an SpO 2 below or equal to 91% with room air without the need for mechanical ventilation. The starting flow for HFNC treatment depended on the child's weight: 5 L/min for 3-4 kg, 6 L/min for 4-7 kg and 8 L/min for 8-10 kg. The FiO 2 was adjusted to keep the SpO 2 at 92%-95%. HFNC treatment was ceased when the FiO 2 had been 21% for two hours and the flow had been 5-8 L/min for the same amount of time.
The analyses were performed with SPSS version 24 (SPSS Inc, Chicago, IL, USA). We used descriptive statistics, and the results were presented as unweighted and weighted means and medians and ranges. Each hospital was given a weighted index, depending on the number of infants born in the catchment area of the hospital in 2015. The MannWhitney U test was used in the statistical analyses. The surveillance period was seven months, including the RSV epidemic, and we did not make any corrections when we calculated the incidences, which were expressed as per year.
RESULTS
The age-specific mean incidence of bronchiolitis treated with HFNC between November 1, 2015 and May 31, 2016 in infants under the age of one in 15 of 17 hospitals was 3.8 per 1000 per year, with a range of 1.3-8.7 and 95% confidence interval (95% CI) of 2.4-5.2. We excluded one central hospital that did not supply the relevant data and one small central hospital that supplied an age-specific incidence of 34.1 per 1000 due to long distances to intensive care facilities, as this outlier would have artificially skewed the overall mean (Table S1 ). In the latter hospital, all infants with bronchiolitis who needed oxygen were treated with HFNC. Most (86.5%) of the HFNC treatments were given on the paediatric wards and only 13.5% were provided in the PICU or other intensive care units.
We found that 10 hospitals provided instructions on how to start HFNC, which equated to a weighted percentage of 71.1%, and seven of those hospitals told staff how to wean patients off and cease HFNC, which was a weighted percentage of 60.6%. The other seven hospitals (28.9%) did not provide instructions on starting or weaning HFNC (Table 1) . Nasogastric tubes were routinely inserted in nine hospitals, which equated to a weighted percentage of 40.1% and short-term fluids were administered intravenously in five hospitals, which was a weighted percentage of 30.2% (Table 1 ). The comparison of crude and weighted percentages suggests that instructions, especially those for weaning off and ceasing HFNC, were more likely to be present in large hospitals, but the routine insertion of nasogastric tubes was more common in small hospitals ( Table 1) .
The presence of instructions for starting HFNC was not significantly associated with the number of infants in the area or the number of HFNC treatments provided by the hospital (data not shown). However, the presence of instructions for weaning off HFNC was significantly associated with the number of infants in the area, with a median of 2580 if instruction were present versus 2257 if they were not present (p = 0.019). The presence of weaning off instructions was also significantly associated with the number of HFNC treatments provided by the hospital, with a median of 17 if they were present versus 11 if they were not present (p = 0.012). This meant that large hospitals that treated more patients with HFNC were more likely to also provide instructions for weaning off and ceasing HFNC.
The most important indication for HFNC was reduced SpO 2 and the limit varied between 90% or less and 95% or less, with a weighted median of 91%. The target SpO 2 during HFNC varied between 90% or more and 95% or more, with a weighted median of 91%. The starting FiO 2 varied from 21% to 50%, with a weighted median of 21%. The starting flow and maximum flow during HFNC were given for an infant weighing 10 kg and the weighted medians were 10 L/min (4-20 L/min) and 20 L/min (7-50 L/min), respectively.
The weaning protocols varied substantially ( Table 2 ). The minimum weaning time, expressed as a weighted median, ranged from eight hours to 20 hours. The minimum flow rate when the clinical staff was ready to end HFNC ranged from 4 to 5 L/min and the FiO 2 was 30%, with all figures expressed as weighted medians. The weaning times of HFNC were shorter, and the flow rates and FiO 2 were higher, if the hospital provided weaning instructions ( Table 2) .
DISCUSSION
There were three main results to emerge from the present questionnaire-based study on clinical practices for HFNC treatment of infants with bronchiolitis in Finnish children's hospitals during the RSV epidemic in winter 2015-2016. First, the mean incidence of HFNC treatments was 3.8 per 1000 per year in infants under 12 months old in the general population, which means that around 0.4% of the age cohort was treated with HFNC in the hospital during that epidemic. Second, the instructions on when and how to start HFNC therapy for bronchiolitis were present in 71% of the hospitals, but only 61% of the hospitals provided instructions on when and how to wean the bronchiolitis patients off HFNC therapy. These percentages were weighted, and were higher than the crude percentages, which means that large hospitals were more likely to provide instructions than small hospitals. The presence of weaning instructions was associated with a shorter weaning time. Third, the great majority (85%) of HFNC treatments were successfully given on the paediatric wards. A 2014 paper, published before the RSV epidemic covered by this study, quantified the incidence of bronchiolitis in infants admitted to the emergency room at less than six months of age as 37 per 1000 in Finland and 70% of cases were treated in hospital, which means that the incidence of hospitalisation was 26 per 1000 per year (14) . In the present study, the mean incidence of bronchiolitis treated with HFNC at <12 months of age was 3.8 per 1000 per year. No data are available on the incidence of bronchiolitis hospitalisation during the winter of 2015-2016 epidemic, which the present study covers. If we apply the incidence figures presented above, we can estimate that around 15% of infants hospitalised for bronchiolitis were treated with HFNC, which does not suggest any substantial overuse of HFNC. In one hospital, all bronchiolitis patients who needed oxygen support were treated with HFNC if there was a device free. That hospital was small, had limited paediatric intensive care facilities and was situated a long way from the tertiary hospital. As it was an obvious statistical outlier, it was not included in the mean incidence quoted above as that would have artificially skewed the figure.
The indications for starting HFNC treatment did not substantially differ between the Finnish children's hospitals, despite the fact that some did not provide formal instructions. The limits of hypoxia that were treated with oxygen support varied between an SpO 2 of 90-95%, but similar variations can be seen in the international bronchiolitis guidelines (3). In the Finnish bronchiolitis guidelines, the lowest SpO 2 that did not require oxygen administration was set at 92% (15) , which was close to the weighted median (91%) observed in the present study.
The starting flow rates were in accordance with the instructions given by the manufacturers of the devices, but during HFNC treatment the hospitals reported surprisingly high maximal flows of 20 L or even higher. Distending airway pressure depended on the size of the patient, the flow rate and the diameter of the nasal cannula compared to the nares (8, 16 ). There have not been any studies that compared flows above 10 L/min and distending airway pressure in infants (5), but higher flows up to 50 L/min have been used in older children and adults (17, 18) . The lack of studies, together with the case reports on serious air leakage in children treated with HFNC (19) , indicate that caution is needed with flows that are higher than 10 L/min in infants.
The average weaning time varied from three hours to 48 hours in those 12 children's hospitals that reported the time periods. Detailed instructions for weaning were present in seven of them. The weaning time was shorter, and the flow and FiO 2 just before the HFNC ended were higher, if the instructions for weaning were available. It was evident that there was a risk of using unnecessarily slow weaning protocols, as most of the paediatric experience has been using HFNC with neonates, who need to be weaned slowly, for example by reducing the flow rate by 0.5 L/min per hour, when the maximum rates are not needed anymore (5) . In contrast, in infants with bronchiolitis, the reduction rate can be 1.0 L/min per hour or even a more rapid reduction (5) .
The recommended flow when doctors were ready to end HFNC treatment varied between 2 and 8 L/min. When the flow is 2 L/min or less, it is not defined as high-flow treatment anymore and the use of the HFNC device does not offer any benefits over standard oxygen administration (20) . A flow of 2-3 L/min is needed to produce distending pressure (21, 22) . In addition, there is evidence that the high flow itself, without any additional oxygen administration, improves oxygen uptake and reduces respiratory work (15) . HFNC use may be harmful if the flow is <2 L/min and there is no air leak through the nares (22) .
Increasing evidence from retrospective studies suggests that HFNC treatment is safe with no substantial risk of complications (8) and prospective pilot studies have reported that treatment can be carried out on the paediatric ward (10, 23) . In the only RCT study published so far on the effectiveness of HFNC treatment, Kepreotes et al. (12) reported that only four minor adverse events occurred in 101 infants with bronchiolitis and none of them led to them being withdrawn from the trial. On the other hand, the risk of adverse effects can be higher, if there is bronchial obstruction caused by smooth muscle contraction, as in wheezy bronchitis or asthma (19, 24) .
The main impact of HFNC therapy may be the reduction of PICU treatment, which is much more expensive than treatment on the ward (9,10,25). As seen in the only RCT study, HFNC may have a special role as rescue therapy to prevent or shorten intensive care (12) or to reduce the need to transfer patients to tertiary hospitals (13) . We found that 85% of the HFNC treatments in the present study were carried out on paediatric wards and the doctors did not report any substantial complications. Nasogastric tubes were routinely used for HFNC-treated infants in more than half of the hospitals we surveyed. Interestingly, the weighted percentage was lower than the crude percentage, which means that this routine was common in small hospitals. Nasogastric tubes were not routinely used in the only RCT on HFNC in infants with bronchiolitis, and the authors did not report cases with substantial abdominal distension (12) .
The present study had some limitations. It is difficult to say how well the answers given by the head doctors, or by the senior doctors who were responsible for bronchiolitis treatment in the hospitals, reflected the real practices in the departments. On the other hand, our aim was to evaluate whether there were instructions on HFNC treatment for bronchiolitis and, if present, what those recommendations were. Our aim was not to evaluate how the patients were actually treated. The strength of the study is that we received completed questionnaires from all but one of the eligible hospitals and the answers covered more than 77% of all infants born in Finland in 2015 when expressed as a weighted percentage.
CONCLUSION
The mean incidence of HFNC treatment was 3.8 per 1000 in infants who were <12 months of age, which suggests that HFNC was actively used, but not overused, in bronchiolitis treatment in Finland. We found that 71% of hospitals provided instructions how to start treatment, but only 61% provided instructions for weaning. Instructions are particularly needed for weaning to avoid unnecessary long treatment times. Well-designed randomised controlled studies on HFNC treatment in bronchiolitis are needed before any evidence-based guidelines can be constructed. 
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Table S1 Basic data on the hospital districts included in the study, including the incidence of HFNC treatments per 1000 infants aged less than 12 months in the hospital district.
